On the recordMarch 20, 2018
A bill I am sponsoring will require the Food and Drug Administration to provide more clarity through a guidance on how these stakeholders can utilize the accelerated approval and breakthrough therapy programs to expedite the availability of innovative therapies for pain and addiction.
Source
congress.gov




